CRA provided expert reports and trial testimony in trade secret litigation concerning an early-stage oncology product candidate. Plaintiff claimed that the alleged misappropriation led to accelerated development of a competing potential treatment. CRA quantified unjust enrichment using a methodology that measured the value associated with accelerated development, recognizing advantages associated with early versus late entry into the marketplace.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...